ENDRA Life Sciences (NDRA) Debt to Equity (2020 - 2023)

ENDRA Life Sciences has disclosed Debt to Equity across 4 years of filings, most recently posting $0.01 for Q4 2023.

• In Q4 2023, Debt to Equity rose 27.31% year-over-year to $0.01; the TTM figure through Dec 2023 stood at $0.01 (up 27.31% YoY), while the FY2023 annual figure was $0.01, up 27.31% from the prior year.
• Debt to Equity retreated to $0.01 in Q4 2023, from $0.01 in the prior quarter.
• Over the last five years, Debt to Equity for NDRA reached as high as $0.35 in Q2 2020 and fell as low as $0.0 in Q1 2021.
• The 4-year median for Debt to Equity is $0.0 (2022), against an average of $0.04.
• Annual changes were most pronounced in 2021 — Debt to Equity slumped 99.45% — and 2022, when it soared 96.86%.
• A 4-year view of Debt to Equity shows it stood at $0.05 in 2020, then plunged by 94.38% to $0.0 in 2021, then jumped by 49.69% to $0.0 in 2022, then climbed by 27.31% to $0.01 in 2023.
• According to Business Quant data, Debt to Equity over the past three periods registered $0.01, $0.01, and $0.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.